Laminin activates the p185HER2 oncoprotein and mediates growth inhibition of breast carcinoma cells
1996

Laminin and its effect on breast cancer cells

Sample size: 887 publication Evidence: moderate

Author Information

Author(s): E Tagliabue, E Ardinil, R Pellegrinil, M Campigliol, R Bufalino, M Jeschke, B Groner, MI Colnaghil, S Menard

Primary Institution: Istituto Nazionale Tumori, Milan, Italy

Hypothesis

Does laminin activate the p185HER2 oncoprotein and inhibit the growth of breast carcinoma cells?

Conclusion

Laminin inhibits the growth of breast carcinoma cells that overexpress p185HER2 and its prognostic significance varies based on laminin production.

Supporting Evidence

  • Laminin treatment resulted in a 40% inhibition of cell growth in p185HER2-positive cell lines.
  • p185HER2 overexpression was associated with poor prognosis in laminin-negative tumors.
  • In laminin-producing tumors, p185HER2 overexpression did not correlate with tumor aggressiveness.

Takeaway

Laminin helps some breast cancer cells grow slower, but if the cancer cells make laminin, it doesn't seem to matter as much.

Methodology

In vitro and in vivo studies were conducted on breast carcinoma cell lines and archival tumor sections to analyze the interaction between laminin and p185HER2.

Limitations

The study does not establish a direct binding between laminin and p185HER2, suggesting the interaction may involve other molecules.

Participant Demographics

887 patients with primary breast cancer, with varying levels of p185HER2 and laminin production.

Statistical Information

P-Value

p<0.01

Statistical Significance

p<0.01

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication